CD55 and neoplasm: Initially, the evidence for the importance of CDC in anti-cancer mAb effector functions was demonstrated through in vitro studies where it was found that tumor cells overexpress complement defence molecules such as CD55 and CD59; and blocking these could enhance the tumor killing capacity of rituximab [25].